Held by 2 specialist biotech funds
# Signal Note: Eventide Values-Based Fund Enters XOM This position acquisition is notable given Eventide's explicit values-based mandate typically focused on healthcare innovation and biotech. The $7.5M XOM stake suggests the firm may be recognizing energy transition opportunities or dividend yield in a rising rate environment, diverging from core biotech allocation strategy. Without disclosed rationale, this appears to be either a tactical portfolio rebalancing or a shift in ESG assessment of energy majors' decarbonization efforts—worth monitoring for signaling intent.